On Oct 9, we issued an updated research report on
Bruker Corporation ( BRKR Quick Quote BRKR - Free Report) . The company’s recent acquisition and collaborations are a strategic fit. However, adverse currency fluctuations remain a drag. The stock currently carries a Zacks Rank #3 (Hold).
A year-over-year fall in second-quarter 2020 revenues across all reporting segments and major geographies due to business disruptions is concerning. Contraction of both margins is also worrying. The company’s inability to provide any financial guidance also raises apprehensions. Moreover, exposure to unfavorable foreign exchange fluctuations, stiff competition and macroeconomic woes pose challenges to Bruker.
The company’s exposure to the hostile foreign exchange fluctuations is a cause for concern as it conducts the majority of its business in the international markets. Further, a competitive landscape and supply issues stemming from the coronavirus pandemic pose a persistent threat to the company.
Over the past six months, Bruker has underperformed the
industry it belongs to. The stock has gained 13.2% compared with the industry’s 30% rise.
On a positive note, Bruker ended the second quarter with better-than-expected earnings. The successful installation and customer acceptance of the Avance system bode well. The potential of the Nano Group, PCI and the MALDI Biotyper is also encouraging.
The company has several Bruker NANO products that are being assembled and tested in Malaysia and by 2022, management expects more than $50 million of revenues to be generated from Penang.
In May, Bruker launched the world’s first commercial MALDI-2 post-ionization (PI) source, which is now available as an option on the timsTOF fleX ESI/MALDI mass spectrometer. It also unveiled additional unique TIMS/PASEF-enabled 4D proteomics methods.
In the same month, the company announced the successful installation and customer acceptance of the world’s first Avance NEO1.2 GHz NMR system in Italy. In July, the same was announced in Switzerland.
Further, Bruker has been making notable efforts to combat the coronavirus crisis. Its microbiology and infectious disease diagnostics portfolio added a SARS-CoV-2 PCR test, and the NMR and mass spec systems used in critical disease, therapeutic and vaccine research.Bruker in July introduced its FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay for higher specific detection of the SARS-CoV-2 virus. Notably, the assay already received the CE Mark and is available on the Bruker Hain FluoroCycler XT real-time PCR system as well as on other commonly available thermocyclers.
Some better-ranked stocks from the broader medical space are QIAGEN N.V. (
QGEN Quick Quote QGEN - Free Report) , Thermo Fisher Scientific Inc. ( TMO Quick Quote TMO - Free Report) and Boston Scientific Corporation ( BSX Quick Quote BSX - Free Report) .
QIAGEN’s long-term earnings growth rate is estimated at 17.2%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently carries a Zacks Rank #2.
Boston Scientific’s long-term earnings growth rate is estimated at 13%. The company presently carries a Zacks Rank of 2.
Zacks’ 2020 Election Stock Report:
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Check out the 2020 Election Stock Report >>